Artelo Biosciences, Inc. (NASDAQ:ARTL – Get Free Report) was the target of a large growth in short interest during the month of June. As of June 15th, there was short interest totalling 13,700 shares, a growth of 39.8% from the May 31st total of 9,800 shares. Approximately 0.4% of the shares of the company are sold short. Based on an average daily volume of 11,500 shares, the days-to-cover ratio is currently 1.2 days.
Artelo Biosciences Stock Up 2.9 %
Artelo Biosciences stock opened at $1.34 on Monday. Artelo Biosciences has a twelve month low of $1.15 and a twelve month high of $2.98. The stock has a market cap of $4.33 million, a P/E ratio of -0.42 and a beta of 1.43. The company’s 50-day moving average price is $1.36 and its two-hundred day moving average price is $1.43.
Artelo Biosciences (NASDAQ:ARTL – Get Free Report) last announced its earnings results on Monday, May 13th. The company reported ($0.78) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.05) by $0.27. Equities analysts anticipate that Artelo Biosciences will post -2.09 earnings per share for the current fiscal year.
Analyst Upgrades and Downgrades
Get Our Latest Analysis on Artelo Biosciences
Artelo Biosciences Company Profile
Artelo Biosciences, Inc, a clinical stage biopharmaceutical company, develops and commercializes therapeutics that target lipid-signaling pathways in the United States. It's product candidate pipeline includes ART27.13, a synthetic dual cannabinoid G protein-coupled receptor agonist, which is in Phase 1b/2a clinical trial for the treatment of anorexia associated with cancer; ART12.11, a synthetic cannabidiol cocrystal for the treatment anxiety, post-traumatic stress disorder, epilepsy, inflammatory bowel disease, and other potential indications; and ART26.12, a fatty acid binding protein 5 inhibitor for treating chemotherapy induced peripheral neuropathy, diabetic neuropathy, prostate cancer and breast cancer, pain, dermatologic conditions, and anxiety disorders.
Featured Articles
- Five stocks we like better than Artelo Biosciences
- The 3 Best Retail Stocks to Shop for in August
- Upwork Stock’s Outlook: Numbers Solid Despite Gen-AI Challenges
- Stock Splits, Do They Really Impact Investors?
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- The Role Economic Reports Play in a Successful Investment Strategy
- MarketBeat Week in Review – 6/24 – 6/28
Receive News & Ratings for Artelo Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Artelo Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.